FEATURED EDITORIAL
Drawing from experiences with ongoing work at AnaptysBio, Inc., senior VP of research Martin Dahl, Ph.D., shares three considerations when developing immune cell modulators to treat and modify inflammatory disease.
- Araris Doubles Down With Dual-payload ADC
- AI Is A Tool — Not A Replacement — For Human Innovation In Drug Discovery
- Does Targeting Macrophages Hold The Key For Treating Cancer?
- Great siRNA Science Or Savvy Business Acumen? You Need Both
- The Search For A Chemotherapy-Free Treatment For Patients With Blood Cancer
- Bridge RNAs: Principles, Applications, And Challenges
- Is Your Lab Ready For A LIMS Implementation?
FEATURED APPLICATION CONTENT
-
Explore the results of a study focusing on the early stages of the CAR T cell workflow, specifically the initial washing of leukapheresis followed by the isolation of T cells.
-
Discover how you can achieve a final mAb concentration above 200 g/L while maintaining critical quality attributes.
-
Learn about a rapid, high-throughput method for determining the E/F ratio in the AAV drug product that is well-suited for screening both crude and purified AAV samples.
-
Gain insight into how a high-throughput capsid assay for rapid AV quantification was developed using an innovative Bio-Layer Interferometry (BLI) platform that offers high precision and reliability.
-
Examine the performance of a biosensor for AAV capsid titer measurement that offers high-precision, broad AAV serotype binding specificity, and more.
-
To address concerns about using organic solvents in the ADC process, extractables studies were conducted on a disposable chromatography column housing and two different disposable flow paths.
-
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
-
A healthcare manufacturer facing space constraints and regulatory pressures outsourced their stability storage needs to another company, resulting in reduced costs and focus on core competencies.
-
When facing a malfunction, having an effective disaster recovery plan can make the difference between a swift fix, and losing your samples and time.
-
A pharmaceutical company facing storage space issues decided to outsource their reference samples to Q1 Scientific, a stability storage service provider, resulting in cost savings.
-
Partnering with a leader in outsourced stability storage is revolutionizing the pharmaceutical and medical device industry to ensure product quality and compliance.
-
Testing for nitrosamines — potential carcinogens found in food, beverages, cosmetics, and pharmaceuticals — is essential in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and drug products to ensure safety and compliance.
FEATURED NEWS HEADLINES
- Charles River And Lundbeck Enter Agreement Utilizing AI-Powered Logica To Advance The Discovery Of Novel Drugs For Neurological Disease
- VeriSIM Life Announces Collaboration With Mayo Clinic To Accelerate New Drug Development
- CAMP4 Enters Strategic Research Collaboration To Advance Novel Regulatory RNA-Targeting Medicines For Rare Genetic Conditions
- CellarisBio Delivers Real-Time Cell Target Engagement System For Challenging Drug Targets
- Papillon Therapeutics Receives Orphan Drug Designation From The U.S. Food And Drug Administration For PPL-002 For The Treatment Of Danon Disease
- Potential Target For Cataract Drug Development
- Adnexus Biotechnologies Unveils Sutra, A Game-Changing AI Platform For Drug Discovery And Infectious Disease Research
- Japan Tobacco Inc. And D-Wave Announce Collaboration Aimed At Accelerating Innovative Drug Discovery With Quantum AI
- Astria Therapeutics Receives FDA Orphan Drug Designation For Navenibart (STAR-0215) For The Treatment Of Hereditary Angioedema
- Seeing Double: Designing Drugs That Target 'Twin' Cancer Proteins
ARCHIVED NEWSLETTER
- 10.08.24 -- Tips For Addressing Vaccine Demand – No Matter Your Therapeutic Background
- 10.08.24 -- Great siRNA Science Or Savvy Business Acumen? You Need Both
- 10.02.24 -- Dig Into Ideas, Data, And Examples Of Bioprocessing Intensification Strategies
- 10.01.24 -- Industrializing mRNA Therapeutics
- 10.01.24 -- AI Is A Tool — Not A Replacement — For Human Innovation In Drug Discovery